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Abstract
Background Fixed combination calcipotriol as hydrate
(Cal) 50 lg/g plus betamethasone as dipropionate (BD)
0.5 mg/g aerosol foam is an alcohol-free treatment for
psoriasis. Betamethasone 17-valerate 2.25 mg (BV)-medi-
cated plasters are recommended for treating psoriasis pla-
ques localized in difficult-to-treat (DTT; elbow, knee,
anterior face of the tibia) areas.
Objective The aim of this study was to compare the effi-
cacy of Cal/BD foam with BV-medicated plaster in
patients with plaque psoriasis.
Methods In this phase IIa, randomized, single-center,
investigator-blinded, 4-week study, both Cal/BD foam
and BV-medicated plaster were applied once daily to six
test sites (three for each treatment). The primary efficacy
endpoint was absolute change in total clinical score
(TCS; sum of erythema, scaling, and infiltration); sec-
ondary endpoints were changes from baseline in each
individual clinical score, ultrasonographic changes (total
skin and echo-poor band thickness), and safety; and post
hoc analysis was change from baseline in TCS on DTT
areas.
Results Thirty-five patients were included. Least-squares
mean change in TCS from baseline was significantly
greater for Cal/BD foam (-5.8) than BV-medicated plaster
(-3.7; difference -2.2; 95% confidence interval -2.6 to
-1.8; p\ 0.001); greater changes for Cal/BD foam were
observed from day 8 for each clinical sign. Absolute total
skin and echo-poor band thickness change was significantly
greater for Cal/BD foam than for BV-medicated plaster
(both p\ 0.001). Post hoc analyses showed that Cal/BD
foam was significantly more effective than BV-medicated
plaster on DTT areas after 4 weeks (p\ 0.001), and both
treatments were well tolerated.
Conclusion Cal/BD foam demonstrated superior efficacy
versus BV-medicated plasters, including on DTT areas, in
patients with plaque psoriasis.
Clinical trial registration number: NCT02518048.
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Key Points
Fixed combination calcipotriol as hydrate (Cal)
50 lg/g plus betamethasone as dipropionate (BD)
0.5 mg/g aerosol foam and betamethasone
17-valerate 2.25 mg (BV)-medicated plasters are
efficacious and safe topical treatments for plaque
psoriasis; the latter is also recommended for treating
plaques localized on difficult-to-treat (DTT; elbow,
knee, anterior face of the tibia) areas.
Cal/BD aerosol foam demonstrated significantly
greater improvement in clinical signs of psoriatic
plaques compared with BV-medicated plasters.
Furthermore, Cal/BD aerosol foam was significantly
more effective than BV-medicated plasters on DTT
areas, as shown in post hoc analyses.
Cal/BD aerosol foam may provide a more successful
treatment outcome in patients with plaque psoriasis
than some of the currently available topical
therapies, regardless of plaque location.
1 Introduction
Psoriasis vulgaris is an immune-mediated, chronic
inflammatory disorder characterized by plaques of scaly,
thickened skin [1–3]. The most common topical therapies
for treating mild-to-moderate psoriasis vulgaris are corti-
costeroids and vitamin D3 analogs, which are used either
alone or in combination [4, 5]. Fixed combination cal-
cipotriol 50 lg/g (Cal) and betamethasone dipropionate
0.5 mg/g (BD) in ointment and gel formulations are
established first-line topical treatments [6]. However,
patient adherence to topical therapies remains an issue,
mostly because of the time-consuming and inconvenient
nature of daily treatment application [7, 8].
In order to address the different needs of patients,
alternative topical formulations and methods of adminis-
tration have been developed. Cal/BD aerosol foam (En-
stilar; LEO Pharma, Copenhagen, Denmark), an alcohol-
free, paraffin-based formulation with emollient properties,
was developed with the aim of addressing these needs
[9–14]; this aerosol formulation becomes supersaturated
when applied to the skin, leading to increased bioavail-
ability and improved clinical efficacy [14]. A previous
plaque test study demonstrated that Cal/BD aerosol foam
had significantly greater efficacy over 4 weeks of treatment
than Cal/BD ointment [12]. In the recent phase III, ran-
domized PSO-ABLE study, Cal/BD aerosol foam demon-
strated significantly greater efficacy at 4 weeks compared
with 8 weeks of treatment with Cal/BD gel [15].
Betamethasone 17-valerate (BV) is a corticosteroid used in
the treatment of psoriasis vulgaris and other inflammatory
skin disorders. Potent BV-medicated plasters, containing
2.25 mg BV (Betesil medicated plaster, manufactured by
Altergon, Morra De Sanctis, Italy), are marketed as being
suitable for plaques localized in difficult-to-treat (DTT)
areas such as knees, elbows, and the anterior face of the
tibia. The plaster can be trimmed to cover psoriatic plaques
exactly and deliver the active ingredient to the affected
area specifically.
The aim of this study was to compare the efficacy of
Cal/BD aerosol foam with BV-medicated plasters using a
psoriasis plaque test design modified from the method
developed by Dumas and Scholtz [16].
2 Patients and Methods
2.1 Patients
Eligible patients (aged C18 years) with psoriasis vulgaris,
with preferably three (or at least two) plaques on their
arms, legs, and/or trunk, were recruited. In patients with
three plaques, each plaque had to be large enough to
accommodate two test sites, while patients with two pla-
ques needed to have one plaque that could accommodate
four test sites and another that could accommodate two test
sites. Each test site had an area of 5 cm2, with at least 2 cm
between the test sites. Patients were required to have
stable psoriasis based on the difference in total clinical
score (TCS; sum score of erythema, scaling, and infiltration
for a particular test site) between screening and baseline
visits (maximum 28 days), as well as plaques with a TCS
of 4–9 (inclusive) and a score of C1 for each item. Patients
with a change of more than one point in any of the clinical
signs were excluded.
Patients receiving systemic treatment with biological
therapies with a possible effect on psoriasis (etanercept
within 4 weeks prior to randomization; adalimumab or
infliximab within 8 weeks; ustekinumab within 16 weeks;
other biological therapies within 4 weeks or five half-lives
[whichever was longer]) were excluded from the study.
Other exclusion criteria included systemic treatment (other
than with biological therapy, e.g. retinoids, immunosup-
pressants) within 4 weeks prior to randomization; treat-
ment with psoralen combined with ultraviolet A therapy
within 4 weeks or ultraviolet B therapy within 2 weeks;
potent or very potent (WHO group III–IV) corticosteroids
within 4 weeks; WHO group I–II corticosteroids within
2 weeks, except if used for scalp and/or facial psoriasis
treatment; any concomitant medical or dermatological
disorders that might preclude accurate evaluation of
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psoriasis on test areas; use of emollients within 1 week;
and initiation of, or expected changes to, concomitant
medication that may affect psoriasis, such as b-blockers,
antimalarial drugs, lithium and angiotensin-converting
enzyme (ACE) inhibitors, within 2 weeks.
2.2 Study Design
This was a phase IIa, single-center, investigator-blinded,
within-patient controlled, randomized, 4-week study
(ClinicalTrials.gov identifier NCT02518048) conducted in
France (Centre de Pharmacologie Clinique Applique´e a` la
Dermatologie, Nice, France). The protocol was approved
by the relevant independent Ethics Committee and appro-
priate regulatory authorities. The study was performed in
accordance with the Declaration of Helsinki and all
patients provided written informed consent prior to
enrolment.
Each patient received both Cal/BD aerosol foam and
BV-medicated plaster once daily (6 days per week,
excluding Sundays, for a total of 28 days) to enable
intraindividual comparisons. Both treatments were applied
by clinical personnel to a total of six test sites (three for
each treatment) and, to ensure blinding, were later removed
by someone other than the investigator. BV-medicated
plasters were cut into test site size for application and
maintained with hypoallergenic dressing. The amount of
Cal/BD aerosol foam (50 mg) was sprayed onto test sites
that were delimited by an adhesive ring, gently rubbed into
the skin using a gloved finger, and covered with a non-
occlusive gauze.
During the study, patients were not allowed to use any
medication that could interfere with the trial results,
including those requiring washout. Treatments that were
permitted during the study included inhaled corticosteroids,
neutral emollients on psoriasis plaques that were not trea-
ted in the trial, and WHO group I–II corticosteroids for the
treatment of scalp and facial psoriasis.
2.3 Assessments
The primary efficacy endpoint was the absolute change in
TCS of Cal/BD aerosol foam and BV-medicated plaster
from baseline to the end of treatment (day 29). The
severity of clinical signs (erythema, scaling, and infiltra-
tion) for each target plaque and test site was assessed by the
investigator using a 7-point scale (range 0 [no evidence],
1.5 [mild-to-moderate] to 3.0 [severe]; TCS total range
0–9), and the absolute change in TCS was calculated from
the mean TCS of the three test sites per treatment.
Secondary efficacy endpoints comparing Cal/BD aerosol
foam and BV-medicated plaster included TCS change at
each visit (i.e. days 4, 8, 11, 15, 18, 22, and 25) compared
with baseline; change from baseline in clinical signs at
each visit; and change in ultrasound measurements of total
skin and echo-poor band thickness (mm) from baseline to
end of treatment (day 29).
A post hoc analysis on the TCS data was conducted to
compare the effect of the two treatments from baseline to
end of treatment on DTT (elbow, knee, and anterior face of
the tibia) and other areas (arm, trunk/back, and areas of the
lower leg, except anterior).
Adverse events (AEs), with a focus on local cutaneous
AEs, were also assessed throughout treatment to evaluate
the safety and tolerability of Cal/BD aerosol foam and
BV-medicated plaster. An AE was defined as any unfa-
vorable and unintended sign, symptom, or disease tem-
porally associated with the use of the investigated
treatments, regardless of its cause. The severity of the AE
was classified into mild, moderate, and severe categories
according to the investigator or sub-investigator’s clinical
judgment.
2.4 Statistical Analysis
Assuming the standard deviation (SD) for the difference in
TCS of 2.0 and a mean difference of 0.75, a sample size of
33 patients and three within-subject replicates of each
treatment was required to detect a difference between Cal/
BD aerosol foam and BV-medicated plaster with 95%
power. All statistical analyses were performed on the full
analysis set (FAS), which comprised all randomized
patients. The absolute changes in TCS (overall and for the
post hoc analysis), total skin thickness, and echo-poor band
thickness from baseline to the end of treatment were ana-
lyzed using a mixed-model analysis of variance (ANOVA),
with treatment as the fixed effect and subject as the random
effect. All significance tests were two-sided using the 5%
significance level and 95% confidence intervals (CIs).
Missing data were imputed using the method of last
observation carried forward (LOCF). All data presented are
LOCF and mean values are least-square means calculated
from the ANOVA analysis.
3 Results
3.1 Patient Characteristics
Thirty-five patients were enrolled and randomized in the
study between September and December 2015 (Fig. 1;
Table 1). All but one patient completed the study (volun-
tary discontinuation).
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3.2 Efficacy
3.2.1 Clinical Assessment
The mean (±SD) baseline TCS was 6.6 ± 0.6 (Table 1).
At all visits after day 4, the change in TCS was greater at
sites treated with Cal/BD aerosol foam compared with BV-
medicated plaster (Fig. 2). The mean change in TCS from
baseline to the end of treatment for Cal/BD aerosol foam
was significantly greater (-5.8) than for BV-medicated
plaster (-3.7; difference -2.2; 95% CI -2.6 to -1.8;
p\ 0.001).
All three clinical signs improved over the course of the
study in both groups. From day 8 to the end of treatment, a
numerically larger change in mean TCS in each of the
clinical signs (erythema, scaling, and infiltration) was
observed in the Cal/BD aerosol foam group compared with
the BV-medicated plaster group (Fig. 3).
3.2.2 Ultrasound Assessment
Mean change in total skin thickness from baseline to the
end of treatment was significantly greater in the Cal/BD
aerosol foam group (-1.0 mm) compared with BV-medi-
cated plaster treatment (-0.6 mm; difference -0.4 mm;
95% CI -0.5 to -0.3; p\ 0.001). A significantly larger
decrease from baseline to the end of treatment in echo-poor
band thickness was also observed with Cal/BD aerosol
foam (-1.3 mm) compared with BV-medicated plaster
(-0.7 mm; difference -0.6 mm; 95% CI -0.7 to -0.4;
p\ 0.001).
3.2.3 Difficult-to-Treat Areas
After 4 weeks of treatment, Cal/BD aerosol foam was
more effective than BV-medicated plaster on all individ-
ual body areas assessed (Fig. 4). When assessing efficacy
on DTT areas (i.e. elbow, knee, and anterior face of the
tibia combined), treatment with Cal/BD aerosol foam led
to significantly greater decreases in TCS compared with
BV-medicated plaster at week 4 (mean change from
baseline in TCS -5.5 vs. -3.4; difference -2.1; 95% CI
-2.7 to -1.6; p\ 0.001). Cal/BD aerosol foam was also
significantly more efficacious on the other areas than BV-
medicated plaster (mean change from baseline in TCS
-6.2 vs. -4.4; difference -1.8; 95% CI -2.4 to -1.2;
p\ 0.001).
Fig. 1 CONSORT diagram. BD betamethasone as dipropionate
0.5 mg/g, Cal calcipotriol 50 lg/g, BV betamethasone 17-valerate
2.25 mg, CONSORT Consolidated Standards Of Reporting Trials
Fig. 2 Mean TCS and 95% CI from baseline to end of treatment
(LOCF): FAS. The p value is calculated for the mean change in TCS
from baseline to end of treatment for Cal/BD aerosol foam versus
BV-medicated plaster. BD betamethasone as dipropionate 0.5 mg/g,
BV betamethasone 17-valerate 2.25 mg, Cal calcipotriol 50 lg/g, CI
confidence interval, FAS full analysis set, LOCF last observation
carried forward, TCS total clinical score
Table 1 Patient demographics and baseline characteristics
Characteristic All patients (n = 35)
Mean age ± SD, years 51.5 ± 12.9
Males:females, n 25:10
Mean disease duration ± SD, years 24.0 ± 12.9
Mean TCSa ± SD 6.6 ± 0.6
SD standard deviation, TCS total clinical score
a Sum of three scores (erythema, scaling, lesional thickness)
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3.3 Safety and Tolerability
A total of 15 patients (42.9%) experienced 20 AEs during
the trial; none were severe. The most frequent AEs were
headache (n = 8; 22.9%), influenza (n = 3; 8.6%), and
oropharyngeal pain (n = 3; 8.6%). No cutaneous AEs were
observed and no other AEs occurred in more than one
patient. No deaths, serious AEs or other significant AEs
were observed.
4 Discussion
Results from this plaque test study demonstrated that Cal/
BD aerosol foam was significantly more efficacious, as
shown by TCS and ultrasound skin thickness assessments,
compared with BV-medicated plaster. The psoriasis plaque
test is a well-established, safe, and relatively low-cost
method for evaluating the efficacy of topical treatments in
psoriasis [12, 16, 17]. As the method combines the
assessment of TCS and ultrasound measurements of skin
thickness, an accurate evaluation of treatment efficacy can
be achieved [12, 16, 17]. Furthermore, the plaque test
enables intraindividual comparisons and increases the
probability of detecting clinically relevant differences with
a limited sample size [18]. The TCS has been used in
several plaque trials and has proven to be both reliable and
useful for the evaluation of selected test sites [12, 16, 17].
In this study, the rate of improvement in TCS and the
individual TCS components (i.e. erythema, scaling, and
infiltration) was more rapid with Cal/BD aerosol foam than
with BV-medicated plaster; a difference was observed
early into treatment (from day 8) and was maintained
throughout the study. The mean change in TCS and total
skin thickness from baseline to day 29, and rapid onset of
symptom improvements for areas treated with Cal/BD
aerosol foam, was similar to that observed in a previous
4-week plaque test study [12]. Occlusion of corticosteroids
is a widely accepted method to enhance the penetration of
Fig. 3 Mean change in a erythema, b scaling, and c infiltration from
baseline to the end of treatment (LOCF): FAS. BD betamethasone as
dipropionate 0.5 mg/g, Cal calcipotriol 50 lg/g, BV betamethasone
17-valerate 2.25 mg, FAS full analysis set, LOCF last observation
carried forward
Fig. 4 Mean reduction in TCS between baseline and week 4 on DTT
and other areas (LOCF): FAS. All lower-leg sites were considered as
DTT areas, except for six sites on two patients, which were not on the
anterior face of the tibia. BD betamethasone as dipropionate 0.5 mg/g,
Cal calcipotriol 50 lg/g, BV betamethasone 17-valerate 2.25 mg,
DTT difficult-to-treat, FAS full analysis set, LOCF last observation
carried forward, TCS total clinical score
Calcipotriol ? Betamethasone Aerosol Foam vs. Betamethasone 17-Valerate-Medicated Plaster 359
the medication and improve its efficacy [19]. BV-medi-
cated plasters are occlusive and are specifically recom-
mended for use on psoriasis plaques localized to DTT areas
(i.e. the knees, elbows, and anterior side of the tibia) [20].
A post hoc analysis showed that Cal/BD aerosol foam was
significantly more efficacious than BV-medicated plasters,
even on these DTT areas (p\ 0.001). Cal/BD aerosol foam
and BV-medicated plasters were both well tolerated
throughout the study.
5 Conclusion
Cal/BD aerosol foam demonstrated superior efficacy
compared with BV-medicated plasters, including on DTT
areas of the body. Cal/BD aerosol foam may therefore
provide a more successful treatment outcome in patients
with psoriasis vulgaris than some of the currently available
topical therapies, regardless of plaque location.
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